Announcements Trials
Browse Landscape

Phase

Phase NA 4Phase 4 1Phase 2 1

Status

Completed 5Terminated 3Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Breast Neoplasms 305Carcinoma, Non-Small-Cell Lung 287Colorectal Neoplasms 159Prostatic Neoplasms 158Carcinoma, Hepatocellular 144Neoplasms 137Leukemia, Myeloid, Acute 131Lung Neoplasms 117Squamous Cell Carcinoma of Head and Neck 108Multiple Myeloma 104Triple Negative Breast Neoplasms 102Recurrence 101Pancreatic Neoplasms 96Stomach Neoplasms 94Ovarian Neoplasms 89Neoplasm Metastasis 87Lymphoma, Large B-Cell, Diffuse 81Sarcoma 70Esophageal Neoplasms 68Uterine Cervical Neoplasms 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 67Melanoma 67Brain Neoplasms 67Rectal Neoplasms 64Head and Neck Neoplasms 62Glioblastoma 60Carcinoma, Renal Cell 58Myelodysplastic Syndromes 55Lymphoma 55Esophageal Squamous Cell Carcinoma 54

Interventions

lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Hypertension × Clear all
NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
130 enrolled
CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡